Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
about
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationThe use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.Thalidomide: a treatment option for bleeding GI angiodysplasias in dialysed patientsDifferential surface expression of CD18 and CD44 by neutrophils in bone marrow and spleen contributed to the neutrophilia in thalidomide-treated female B6C3F1 miceThalidomide in multiple myeloma: past, present and future.Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaThe Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.Current multiple myeloma treatment strategies with novel agents: a European perspectiveKidney disease associated with plasma cell dyscrasiasGuidelines for the diagnosis and management of multiple myeloma 2011.Novel approaches for reducing free light chains in patients with myeloma kidney.Current treatments for renal failure due to multiple myeloma.Recent advances in the pathogenesis and management of cast nephropathy (myeloma kidney).Treatment of Relapsed/Refractory Multiple Myeloma.Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.Early response predicts thalidomide efficiency in patients with advanced multiple myeloma.Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.Guidelines on the diagnosis and management of multiple myeloma 2005.
P2860
Q27002668-C4A3542A-965F-4440-9377-DDF0FEA42100Q33864162-20A8E406-1803-407C-94AF-0C3283902528Q35244883-C4A49743-18F1-40EE-822C-A75AFEFDD646Q35573842-4F316537-83D8-426C-B581-B46E01C937C0Q35757592-AF12C6DC-4DF3-4EDD-9669-330816183112Q36616493-1CC67256-F96F-49F5-9E99-130171CF0A3BQ37216472-66D02206-EDA5-444F-B0A6-89C5A0DA385EQ37644252-FF1030B9-C68F-4D5E-B91F-B5B4DC84F9D0Q37677935-CA04709D-8C1D-4A86-9254-EA614301DE34Q37750106-0EEF0DA9-6E15-40A0-A5F1-4016C6EF31A4Q37875193-599A09DD-12D5-4945-9D54-DBA99E8E1D38Q37986358-8FE047D5-3F25-4306-AA8F-1C641D1A8CAEQ38109235-5B321EB5-6836-4869-829F-F601DAF18293Q38802354-8CED62B1-CAEB-4B62-A900-FC3FEBF9C607Q38970597-7A55D758-9430-498E-93C7-95672C0B475EQ41044036-90023419-752A-4F56-B652-FDF78B2E4399Q44597478-04233697-5A68-4FAF-AAAF-52EC57828D44Q44826295-8A4C260C-C10E-43E1-92A7-13D538F22404Q44971622-A9F181A4-F44A-4867-8538-4D3E1F0461D9Q46543493-9F93C521-DA9E-4A80-BC8F-3A9CC3681963Q53556535-8859771A-7D08-4732-B597-7C9D437D8839
P2860
Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Pharmacokinetics of thalidomid ...... and while on and off dialysis.
@en
Pharmacokinetics of thalidomid ...... and while on and off dialysis.
@nl
type
label
Pharmacokinetics of thalidomid ...... and while on and off dialysis.
@en
Pharmacokinetics of thalidomid ...... and while on and off dialysis.
@nl
prefLabel
Pharmacokinetics of thalidomid ...... and while on and off dialysis.
@en
Pharmacokinetics of thalidomid ...... and while on and off dialysis.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics of thalidomid ...... and while on and off dialysis.
@en
P2093
Eriksson T
Scheffler M
Turesson I
P2860
P304
P356
10.1211/0022357022241
P577
2003-12-01T00:00:00Z